We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
U.S. Bioservices will pay $13.4 million to settle a lawsuit concerning allegations the company illegally billed federal and state insurers for prescriptions for Novartis AG’s Exjade in exchange for referrals from the drugmaker, according to a filing from the U.S. Attorney’s Office. Read More
The FDA cited a Montreal drugmaker for refusing to allow an FDA inspector to take photographs during an inspection — and said that alone can lead to a finding that products are adulterated. Read More